Feature
David Cameron Spotlights Oxford-Harrington Rare Disease Centre’s Role in Advancing Rare Disease Treatments
May 27, 2026
David Cameron, Former UK Prime Minister and Chair of the Oxford-Harrington Advisory Council, highlighted the growing impact of the Oxford-Harrington Rare Disease Centre (OHC) in accelerating the development of treatments for rare diseases, at an interview with WKYC Channel 3.
In his interview recorded as part of his visit to the 13th Annual Harrington Discovery Institute Scientific Symposium in Cleveland, Lord Cameron reflected on the personal experiences that continue to shape his commitment to rare disease research and innovation.
Following the death of his son Ivan in 2009 from Ohtahara syndrome, a severe and rare neurological condition, David Cameron championed advances in genomics through the UK’s pioneering 100,000 Genomes Project, which was launched during his time as Prime Minister.
He described how advances in genome sequencing are already changing outcomes for families today, including children with conditions that previously had no clear diagnosis or treatment pathway. He emphasised the importance of making rapid genomic sequencing more widely available in neonatal and paediatric intensive care settings, where earlier diagnosis could lead to faster intervention and improved outcomes.
David Cameron now serves as Chair of the Oxford-Harrington Rare Disease Centre Advisory Council to guide the Centre’s path to translating breakthrough science into new medicines for patients with rare diseases.
The interview also explored the role of the Oxford-Harrington Rare Disease Centre in building a transatlantic model for therapeutic innovation. Established through a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, the Centre supports researchers working to advance promising discoveries toward clinical application.
Discussing the future of rare disease research, Lord Cameron said advances in AI and machine learning could significantly shorten the path from scientific discovery to therapeutic development by helping researchers analyse vast amounts of genomic and clinical information more efficiently.
The conversation additionally addressed broader challenges facing life sciences research, including funding pressures, scientific collaboration, and the need to continue investing in research ecosystems that connect universities, hospitals, biotech companies, and clinicians.